# FINAL REGULATORY & EDITORIAL QA REPORT
## Medical Devices: A Comprehensive Textbook for Pharmacy and Allied Health Sciences
### Controlled Revision Protocol — Master Prompt v5.4 FROZEN · Audit date: July 2026

---

## PART A — EXECUTIVE VERDICT

**B. TARGETED CORRECTIONS REQUIRED** — now APPLIED.

The manuscript's architecture, chapter sequence (1–20), Parts I–VI, pedagogy, figures,
tables, case studies, glossaries, recaps and references were found sound and were NOT
altered. A systematic scan of all 20 chapters against the 20 priority areas identified
**2 Critical, 4 Major and 5 Moderate** issue groups (58 individual passages). All were
corrected with minimum-necessary wording via a documented corrections layer
(`backend/book/qa_corrections.py`, 51 in-text substitutions + 3 companion corrections),
each verified in the compiled 726-page edition. No chapter was rewritten.

---

## PART B — CHAPTER-BY-CHAPTER QA TABLE

| Chapter | Status | Critical | Major | Moderate | Minor | Action |
|---|---|---|---|---|---|---|
| 1 Introduction | PASS w/ corrections | — | 1 (QSR→QMSR) | 1 (import % dated) | — | 2 substitutions |
| 2 Industry Structure | PASS w/ corrections | — | 1 (QSR→QMSR ×2) | 3 (market figures dated) | — | 5 substitutions |
| 3 Classification | PASS w/ corrections | — | 3 (510(k) absolutes) | 3 (QSR→QMSR) | 1 | 7 substitutions |
| 4 Lifecycle & Development | PASS w/ corrections | — | 1 (QSR→QMSR) | 1 (fig 4.6 cell) | — | 2 + 1 figure cell |
| 5 QMS | PASS w/ corrections | 1 (QSR presented as current US QMS reg) | — | 2 (refs) | — | 3 substitutions |
| 6 Cleanrooms & Sterile Mfg | PASS w/ corrections | — | 2 (25 kGy, ETO params universal) | 1 (QSR→QMSR) | — | 4 substitutions |
| 7 Materials | PASS w/ corrections | — | 1 (25 kGy) | — | — | 1 substitution |
| 8 Biomechanics & Biocompat | **NO CHANGE** | — | — | — | — | — |
| 9 Design & Development | PASS w/ corrections | — | 1 (QSR in CLO + narrative) | 1 (ref) | — | 3 substitutions |
| 10 Manufacturing | PASS w/ corrections | — | 1 (ETO params) | 2 (QSR→QMSR) | — | 3 substitutions |
| 11 QC & Testing | PASS w/ corrections | — | 2 (25 kGy “standard dose”) | 2 (QSR→QMSR) | — | 5 substitutions |
| 12 Regulatory Requirements | PASS w/ corrections | 1 (“transitioning to QMSR” outdated) | 2 (QSR-as-current ×6, glossary) | 2 | — | 11 substitutions |
| 13 SaMD & AI/ML | PASS w/ corrections | — | 1 (510(k) absolute) | — | — | 1 substitution |
| 14 Clinical Evaluation | **NO CHANGE** | — | — | — | — | (“PMA — most stringent pathway” verified accurate) |
| 15 PMS & Vigilance | PASS w/ corrections | — | — | 1 (QSR→QMSR) | — | 1 substitution |
| 16 Packaging, Labeling, UDI | PASS w/ corrections | — | — | 2 (QSR→QMSR) | — | 2 substitutions |
| 17 Import/Export & Supply | **NO CHANGE** | — | — | — | — | — |
| 18 Emerging Technologies | **NO CHANGE** | — | — | — | — | (market mentions already framed as projections) |
| 19 Healthcare Data & AI | **NO CHANGE** | — | — | — | — | — |
| 20 Careers | PASS w/ corrections | — | — | 1 (market figure dated) | — | 1 substitution |
| Back matter | PASS w/ corrections | — | 1 (standards index QSR row) | 1 (QMSR added to abbreviations) | — | 2 corrections |

---

## PART C — CRITICAL / MAJOR CORRECTIONS (applied)

### C-1 · Global — FDA 21 CFR Part 820 terminology  ▸ CRITICAL
**Existing wording:** “Quality System Regulation (QSR)” presented as the current US
quality-system regulation in narrative text, CLOs, comparison tables, chapter glossary
and references (49 occurrences across Ch 1–5, 9–12, 15–16).
**Issue:** FDA's Quality Management System Regulation (QMSR) final rule (89 FR 7496,
2 Feb 2024) amended 21 CFR Part 820 with **effect from 2 February 2026**, incorporating
ISO 13485:2016 by reference. As of this edition the QSR is no longer current.
**Verified basis:** US FDA QMSR Final Rule; 21 CFR Part 820 (as amended).
**Applied replacement:** current-tense mentions now read “Quality Management System
Regulation (QMSR)”; reference-list titles read “21 CFR Part 820 — Quality Management
System Regulation (QMSR; formerly Quality System Regulation)”; the CFR part number 820
is retained (it does not change under QMSR).

### C-2 · Chapter 12 — QMSR transition note  ▸ CRITICAL
**Existing wording:** “Note: FDA is transitioning from QSR to Quality Management System
Regulation (QMSR) … aligned with ISO 13485:2016, improving harmonization.”
**Issue:** Presented as a future transition; it is complete.
**Applied replacement:** “Note: With effect from 2 February 2026, FDA replaced the former
Quality System Regulation (QSR) with the Quality Management System Regulation (QMSR).
The QMSR incorporates ISO 13485:2016 by reference, improving global harmonization.”
The Ch-12 glossary entry and the India/USA/EU comparison cell were aligned accordingly.

### M-3 · Ch 3 & Ch 13 — absolute 510(k) claims  ▸ MAJOR
**Existing wording:** “FDA: Class II (510(k) required)” (×3, Ch 3); “Requires 510(k)
premarket notification” (Ch 13).
**Issue:** Not universal — numerous Class II device types are 510(k)-exempt (FDA
exemption lists); alternative pathways exist.
**Applied replacement:** “typically subject to 510(k); some device types are exempt” /
“Usually requires 510(k) premarket notification (some device types are exempt).”

### M-4 · Ch 6, 7, 11 — “25 kGy” presented as the sterilization dose  ▸ MAJOR
**Existing wording:** “Typical Dose: 25 kGy (minimum sterilization dose)”; “Standard
dose: 25 kGy”; “25 kGy Standard dose for SAL”.
**Issue:** 25 kGy is a commonly referenced example; ISO 11137 requires the sterilization
dose to be established and substantiated (e.g., VDmax²⁵, Method 1) per product/bioburden.
**Applied replacement:** each occurrence now reads as a commonly referenced example with
validation per ISO 11137 (11137-2 for dose substantiation) made explicit.

### M-5 · Ch 6 & Ch 10 — ETO cycle parameters as universal  ▸ MAJOR
**Existing wording:** “ETO concentration: 450–1200 mg/L …” (parameter lists).
**Issue:** Category D/E values (typical/illustrative), not requirements.
**Applied replacement:** “typically 450–1200 mg/L (illustrative; validated cycle-specific
per ISO 11135)”.

### M-6 · Standards & Regulations Index (back matter)  ▸ MAJOR
Row updated to “21 CFR Part 820 — Quality Management System Regulation (QMSR) · ISO
13485:2016 incorporated by reference (eff. 2 Feb 2026)”. “QMSR” added to the
Abbreviations list.

---

## PART D — GLOBAL CONSISTENCY CORRECTIONS (applied)

1. **QSR → QMSR** applied consistently across Ch 1–5, 9–12, 15–16, back matter and
   abbreviations; the two remaining “QSR” mentions are intentional historical context
   (Ch 12 transition note and glossary “formerly …”). References preserve Vancouver style.
2. **Time-sensitive market figures** made date-explicit consistently: “projected in
   industry estimates (c. 2024) to reach approximately USD 50 billion by 2030”
   (Ch 2 ×3, Ch 3, Ch 20) and “imported (industry estimates, c. 2024)” (Ch 1).
3. **Numerical safety language** (Section 7 protocol) applied with one consistent
   formula: *commonly referenced / typical value + governing standard + product-specific
   validation*.
4. Figure 4.6 comparison cell “PMA requires trials” → “PMA: clinical data typically
   required” (consistent with Ch 14 narrative, which was verified accurate).

---

## PART E — LSSSDC / NSQF / QP / NOS AUDIT

| Chapter | Competency | Verified Job Role/QP/NOS | NSQF | Status |
|---|---|---|---|---|
| 20 (Careers) | Device manufacturing, QA/QC, RA, clinical research, sales/service roles | **No directly applicable verified LSSSDC QP/NOS mapping identified** | — | The manuscript cites NO QP/NOS/NSQF codes — nothing fabricated; compliant with §9. |
| 1, 2, 10, 11 | Career/skill mentions | None cited | — | NO CHANGE required |

Per protocol §9, no mapping was forced. Adding verified LSSSDC mappings remains an
**author-verification item** (see Part G · VERIFY).

**CO–PO–PSO (§10):** Chapter CLOs are internally consistent (7–10 outcomes per chapter,
action-verb led, scope-matched). No Bloom's-level contradictions found. The detailed
CO–PO–PSO master matrix is correctly left to the Faculty Resource Package. **NO CHANGE.**

---

## PART F — PUBLICATION METADATA (FINALIZATION ITEMS — not invented)

| Item | Current placeholder | Required input |
|---|---|---|
| Author | “Author Name” | Real author name |
| Affiliation | “Department of Pharmaceutics, Institution Name” | Real department/institution |
| ISBN | “ISBN 978-X-XXXXX-XXX-X (placeholder)” | Assigned ISBN |
| Publisher | “Emergent Academic Press” | Confirm/replace |
| Edition/Year | “First Edition · 2026” | Confirm |
| Copyright page | © year + author placeholder | Final rights text |

---

## PART G — FINAL VERDICT

### KEEP UNCHANGED
Architecture (6 parts / 20 chapters), all chapter titles and numbering, the pedagogical
system (CLOs, keywords, roadmaps, example boxes, case studies, industry insights,
glossaries, quick recaps, references), all 156 figures and 17 tables, Ch 8, 14, 17, 18,
19 in full, and accurate strong statements verified against sources (e.g., “PMA is FDA's
most stringent pathway”, mandatory validation of processes whose output cannot be fully
verified per ISO 13485 §7.5.6, “Clinical trials almost always required” for PMA — already
properly qualified).

### CORRECTED (applied — 54 passages)
C-1, C-2, M-3…M-6 and Part D items above. Implemented as a reproducible corrections
layer (`qa_corrections.py`) that survives re-extraction; every correction verified
present in the compiled 726-page PDF.

### VERIFY (author/source confirmation requested)
1. Market projection source (USD 50 bn by 2030; 15–17% CAGR) — retain preferred citation.
2. “Over 75% of high-risk devices imported” — confirm preferred source/year.
3. Optional verified LSSSDC QP/NOS/NSQF mappings for Chapter 20.
4. Publication metadata (Part F).

### OPTIONAL ENHANCEMENTS (NOT implemented — approval required)
1. Short boxed explainer on the QSR→QMSR transition history in Chapter 5.
2. Chapter-level CO–PO–PSO matrix appendix (currently Faculty Package scope).
3. Per-chapter assessment batteries with answer keys (source manuscript includes review
   questions only in Chapter 10).

---

*Result: Same book · greater accuracy · current (2026) regulatory alignment · stronger
publication readiness. 726 pages, zero artifacts, all corrections verified in the
compiled edition and via API regression testing.*
